Targeting Real World Usage In Stroke Treatment
TRUST Registry - Targeting Real World Usage In Stroke Treatment A WallabyPhenox Hemorrhagic Stroke Registry
Phenox GmbH
5,000 participants
Jan 29, 2026
OBSERVATIONAL
Conditions
Summary
TRUST Registry is an observational, prospective, long-term, post-market surveillance registry of subjects treated with WallabyPhenox flow modulation devices, stent systems, bifurcation aneurysm implants including their HPC variants (Hydrophilic Polymer Coating) where applicable as well as coil systems, and other adjunctive medical devices. The overarching purpose of this registry is to carry out a proactive gathering, recording, and analysis of data on the safety, performance and usability of the devices as applied within the routine practice of the participating registry sites.
Eligibility
Inclusion Criteria2
- Subject treated or intended to be treated with at least one target registry device during the procedure (i.e., at least one attempt of introduction into the vasculature of the subject),
- Non-opposition to data collection or informed consent provided by the subject or legal representative as per country-specific legislation.
Exclusion Criteria1
- Participation in an interventional study modifying standard care management for all relevant indications,
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment of aneurysms (saccular or fusiform) and pseudoaneurysms with a Neurovascular Flow Diverter. This includes p64, p64 MW, p64 MW HPC, p48 MW and p48 MW HPC.
Treatment of vascular dissections in the acute and chronic phases with a Neurovascular Flow Diverter. This includes p64, p64 MW, p64 MW HPC, p48 MW and p48 MW HPC.
Treatment of vascular perforations with a Neurovascular Flow Diverter. This includes p64, p64 MW, p64 MW HPC, p48 MW and p48 MW HPC.
Treatment of Arteriovenous fistula with a Neurovascular Flow Diverter. This includes p64, p64 MW, p64 MW HPC, p48 MW and p48 MW HPC.
Treatment of saccular and fusiform aneurysms as well as pseudoaneurysms with pEGASUS HPC. pEGASUS HPC is to be used in combination with coils.
Atherosclerotic vascular stenosis of intracranial arteries treated with pEGASUS HPC.
Treatment of vascular dissections in the acute and chronic phases with pEGASUS HPC.
Treatment of intracranial bifurcation aneurysms with pCONUS 2 or pCONUS 2 HPC.
Treatment of intracranial aneurysms with the available variants of the Avenir Coil System.
Treatment of arteriovenous fistula with the available variants of the Avenir Coil System.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07474935